Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of ZG006 in Metastatic Neuroendocrine Prostate Cancer
CTR20252273Phase 2Active
- Sponsor
- Zelgen
- Start
- Jun 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of alveltamig in Metastatic prostate adenocarcinoma with neuroendocrine differentiation (NEPC), sponsored by Zelgen. Started Jun 2025; status: active.
02
Drugs
alveltamig
03
Conditions
Metastatic prostate adenocarcinoma with neuroendocrine differentiation (NEPC)
Beyond the preview
Go deeper on CTR20252273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252273.